Determinants of left ventricular diastolic dysfunction in hemodialysis patients

Dorin Dragoş¹,²*, Delia Timofte³*, Dorin Ionescu¹,⁴*, Andra-Elena Balcangiu-Stroescu⁵,⁶, Maria Iuliana Ghenu¹,²*, Ileana Adela Vacaroiu⁴,⁷, Maria Mirabela Manea⁸,⁹*

¹Medical Semiology and Nephrology Discipline, Bucharest Emergency University Hospital, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
²1st Internal Medicine Clinic, Bucharest University Emergency Hospital, Bucharest, Romania
³Dialysis Department, Bucharest University Emergency Hospital, Bucharest, Romania
⁴Nephrology Clinic, University Emergency Hospital Bucharest, Romania
⁵Discipline of Physiology, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
⁶Nephrology Discipline, Emergency Clinical Hospital “Sf.Ioan”, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
⁷Nephrology and Dialysis Clinic, “Sf.Ioan” Emergency Clinical Hospital, Bucharest, Romania
⁸Neurology Discipline, National Institute of Neurology and Neurovascular Diseases, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
⁹National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania

# These authors have contributed equally to this work and share first authorship.

Implication for health policy/practice/research/medical education:
In patients on chronic hemodialysis, the prevalence of LVDD is positively correlated with inflammation and oxidative stress markers and with the severity of aortic calcification. The purpose of designing therapeutic strategies is to prevent or slow the course of LVDD, thereby influencing the cardiovascular and general outcomes of these patients.

Please cite this paper as: Dragoş D, Timofte D, Ionescu D, Balcangiu-Stroescu AE, Ghenu MI, Vacaroiu IA, Manea MM. Determinants of left ventricular diastolic dysfunction in hemodialysis patients. J Nephropathol. 2022;11(6):e18393. DOI: 10.34172/jnp.2022.18393.
Introduction

Left ventricular diastolic dysfunction (LVDD) is frequent in Chronic kidney disease (CKD) patients (1), particularly in those on hemodialysis (2). Multiple cardiac/myocardial anomalies acknowledged to exist in CKD patients may explain it (3), including (a) left ventricular hypertrophy (LVH) (4), which is an early occurrence during the course of CKD (5), has a high prevalence in CKD patients and increases death risk (1); (b) myocardial fibrosis as a consequence of both traditional and CKD-associated risk factors (6); (c) wall thickening of the intramyocardial arterioles (7).

Multiple factors seem to concur in inducing these structural changes, including (a) Those increasing the preload (associated with eccentric LVH and increased length of cardiomyocytes), such as hypervolemia, anemia, and the augmented cardiac output demanded by the arteriovenous fistulas or grafts that provide vascular access for hemodialysis (8); (b) Those raising afterload (associated with concentric LVH and increased thickness of cardiomyocytes) – by augmenting arterial impedance due to high blood pressure and calcification-related arterial wall stiffening (5); (c) Others, including inflammation (5,9–11), oxidative stress (5), anemia (12), and metabolic factors, the latter being primarily related to disordered bone and mineral metabolism: increased serum levels of calcium (13), phosphates (13,14), calcium × phosphate product (13), and parathormone (8,13,15), and vitamin D deficiency (16).

Objectives

This study aimed at uncovering the clinically relevant correlates (which might include putative determinants) of LVDD in hemodialysis patients, with the perspective that they might constitute in the future the basis for prevention programs or interventions.

Patients and Methods

The present study is an observational study performed on 51 patients (30 males, 21 females, age 59.76 ± 13.24 years) on hemodialysis treatment (for 2-84 months, with an average ± standard deviation of 40.76 ± 21.64 months, with an ultrafiltration of 1.95 ± 0.93 L) in the hemodialysis department of the university emergency hospital, Bucharest, Romania.

The diagnosis of LVDD was made according to the current European and American guidelines (17) as they are readily applicable in clinical practice, well correlated with invasive measurements, and reliable in predicted outcome (18).

The imaging atherosclerosis markers (IAMs) employed in our study were: 1. valvular calcifications (both aortic and mitral), estimated by transthoracic cardiac ultrasound, and 2. arterial atherosclerosis burden reflected by: (a) atheroma plaques (both carotid and femoral) and common carotid intima-media thickness, evaluated by vascular ultrasound, and (b) aortic calcification score as defined by Kauppila et al (19), calculated on lateral lumbar films (in which the spine was visible from eleventh thoracic to the second sacral vertebral).

Certified, experienced sonographers and radiologists blinded to the results of lab tests performed the imaging examinations.

In each patient, two radiologists, each blinded to the assessment of the other, calculated the aortic calcification score. The value included in the statistical analysis was the average of the two independent estimations.

The inflammation markers employed in our study were; C-reactive protein (CRP), fibrinogen, tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6).

The nutrition status was assessed by means of anthropometric (body mass index), biochemical (serum levels of albumin, cholesterol, and triglycerides), and diet related (normalized protein catabolic rate) parameters.

The vascular access was by tunneled cuffed catheters in 16 patients and by arteriovenous fistula in 35 patients. The primary kidney condition (responsible for the end-stage CKD leading to hemodialysis) was: adult type (dominant) polycystic kidney disease (in 5 patients), diabetic nephropathy secondary to type I diabetes mellitus (2 patients), diabetic nephropathy secondary to type II diabetes mellitus (8 patients), focal segmental glomerulosclerosis with nephrotic syndrome (1 patient), IgA nephropathy (1 patient), presumed (not histologically proven) glomerulonephritis (6 patients), congenital renal hypoplasia (1 patient), traumatic or surgical kidney loss (1 patient), drug-induced interstitial nephropathy (1 patient), pyelonephritis due to acquired obstructive uropathy (2 patients), kidney tumor (1 patient), renal vascular disease due to hypertension (21 patients), renal vascular disease due to polyarteritis nodosa (1 patient).

Statistical analysis

The correlations between two categorical parameters (such as LVDD and degenerative aortic stenosis) were assessed by means of Fisher’s exact test. Chi-square test was also applied in the cases where none of the expected values was less than 5 (20). The correlations between one categorical parameter and one numerical parameter were assessed by Mann-Whitney test. Regression analysis was employed to assess the correlation between two numerical parameters, estimating the strength of the correlation by means of the correlation coefficient and the statistical significance of the correlation by means of t-statistic. R language and environment for statistical computing and graphics (version 4.1.2) was used to perform the statistical
computations. A P value equal to or less than 0.05 was considered as indicator of statistical significance.

**Results**

There were 32 patients with and 19 without LVDD. Table 1 is a summary of the demographic, biochemical, and imagistic features of our patients.

**Associations between LVDD and inflammation- and oxidative stress-related parameters**

Left ventricular diastolic dysfunction appears to have positive statistically significant correlations with serum CRP level (but not with others inflammation markers, such as fibrinogen, IL-6 and TNF-α) and with serum total antioxidant capacity (Figure 1 and Table 2). An intriguing negative statistically significant correlation was also found between LVDD and cortisol level (Table 2).

**Associations between LVDD and demographic and metabolic parameters**

There was no association between LVDD and age, but a tendency to association with male gender was obvious.

**Table 1.** Anthropometric, biochemical, radiological, and ultrasonographic features of the patients

| Continuous parameters (real numbers) | LVDD present | Mean ± SD | Median (q1 -q3) | LVDD absent | Mean ± SD | Median (q1 -q3) |
|--------------------------------------|--------------|-----------|----------------|-------------|-----------|----------------|
| Age (years)                          | 61.22 ± 13.59| 61 (52,75-70,25) | 57.32 ± 12.6 | 55 (49,5-67,5) |
| Body mass index (kg/m²)              | 26.62 ± 5.81 | 25.9 (22.7-29.05) | 27.37 ± 5.36 | 27 (24.2-29.45) |
| Total time on dialysis (months)      | 40 ± 22.69   | 41 (22.25-55.75) | 42.05 ± 20.28 | 43 (31,5-59) |
| Hemoglobin (g/dL)                    | 9.89 ± 1.48  | 10.1 (8.9-11.025) | 9.87 ± 1.87  | 10.3 (8.25-11.15) |
| Daily urine output (mL)              | 439 ± 415    | 200 (162.5-1000) | 642 ± 544    | 600 (200-950) |
| Ferritin (ng/mL)                     | 994 ± 469    | 946 (598.5-1500) | 871 ± 467    | 726 (558-1255) |
| Calcium (mg/dL)                      | 8.37 ± 1.19  | 8.5 (7.8-9.125)  | 8.48 ± 0.62  | 8.6 (8.1-8.85) |
| Phosphorus (mg/dL)                   | 5.34 ± 1.76  | 5 (3.9-6.7)      | 5.41 ± 1.55  | 5.1 (4.5-6.6) |
| Calcium×Phosphorus product (mg²/dL²) | 44.36 ± 15.5 | 39.5 (33.4-57.6) | 46.32 ± 15.21| 40.2 (38.7-57.8) |
| Alkaline phosphatase (IU/L)          | 92.42 ± 64.53| 68 (55-104.75)  | 84.63 ± 39.51| 89 (48.5-101) |
| C reactive protein (mg/dL)           | 13.78 ± 24.34| 5.7 (0.875-14.7) | 3.47 ± 4.74  | 1.9 (0.1-4.7) |
| Fibrinogen (mg/dL)                   | 398 ± 102    | 367 (328-426)   | 351 ± 57     | 364 (297-382) |
| Albumin (g/dL)                       | 3.72 ± 0.58  | 3.8 (3.375-4.2)  | 3.91 ± 0.41  | 3.9 (3.65-4.3) |
| Cholesterol (mg/dL)                  | 151.62 ± 40.95| 140 (129.5-173.5)| 164.47 ± 40.56| 162 (144.5-171.5) |
| LDL-cholesterol (mg/dL)              | 84.44 ± 31.46| 77.2 (63.5-97.65)| 81.95 ± 19.82| 87.8 (66.5-94.5) |
| Triglycerides (mg/dL)                | 127 ± 86     | 108 (63.5-150)   | 137 ± 45     | 142 (107-156.5) |
| Total protein (g/dL)                 | 6.76 ± 0.61  | 6.75 (6.35-7.125)| 6.83 ± 0.51  | 6.9 (6.6-7.1) |
| Uric acid (mg/dL)                    | 6.3 ± 1.22   | 6.4 (5.575-7.125)| 6.55 ± 1.35  | 6.3 (5.45-7.6) |
| Total antioxidant capacity (U/mL)    | 25.99 ± 4.51 | 26.2 (22.9-29.4) | 23.14 ± 4.88 | 22 (20-26.6) |
| NADPH-oxidoreductase (ng/mL)         | 14.95 ± 2.98 | 16 (12.5-17.5)  | 14.31 ± 2.96 | 14.4 (12.1-16.3) |
| Xanthine-oxidase (ng/mL)             | 6.26 ± 0.44  | 6.2 (6-6.6)     | 6.45 ± 0.53  | 6.5 (5.95-6.9) |
| 1.25-dihydroxyvitamin D (pg/mL)      | 316 ± 66     | 307 (265-378)   | 327 ± 47     | 339 (291-356.5) |
| Interleukin 6 (pg/mL)                | 6.97 ± 0.84  | 6.85 (6.575-7.45) | 7.35 ± 1.27  | 7.3 (6.25-7.95) |
| Fibroblast growth factor 23 (pg/mL)  | 27.2 ± 3.37  | 27.95 (24.7-29.3)| 27.08 ± 3.03 | 27.5 (24.1-29.3) |
| Tumor necrosis factor alpha (pg/mL)  | 8.12 ± 0.97  | 8.25 (7.325-8.9) | 8.32 ± 0.98  | 8.2 (7.8-8.95) |
| Cortisol (µg/dL)                     | 13.29 ± 3.9  | 13.4 (10-16)    | 15.89 ± 4.3  | 15.1 (12.5-19.5) |
| Dehydroepiandrosterone (µg/dL)       | 76.78 ± 67.06| 52.2 (34.3-94.8) | 124 ± 210    | 88 (49.2-100) |
| Gamma glutamyl transferase (U/L)     | 50.44 ± 58.7 | 23 (18-48.75)   | 35.53 ± 26.11| 29 (20.5-43.5) |
| Parathormone (pg/mL)                 | 177 ± 223    | 89.4 (36-191)   | 267 ± 284    | 139.4 (47-353) |
| Normalized protein catabolic rate    | 1.13 ± 0.34  | 1.1 (0.9-1.4)   | 1.26 ± 0.33  | 1.3 (1.1-1.45) |
| Intima-media thickness (mm)          | 0.61 ± 0.21  | 0.6 (0.5-0.7)   | 0.54 ± 0.1   | 0.5 (0.5-0.6) |
| Interventricular septum thickness (mm)| 11.66 ± 1.91| 12 (11-13)      | 9.63 ± 4.61  | 11 (10-12.5) |
although the result did not reach statistical significance as computed by chi square test (a chi-square statistic of 3.4943, corresponding to a \(P\) value of 0.06).

No association was found between LVDD and metabolic/nutrition parameters, including body mass index, obesity, overweight, underweight, albumin, cholesterol, triglycerides, calcium, phosphorus, calcium \(\times\) phosphorus product, vitamin D, parathormone, hemoglobin and ferritin.

Associations between LVDD and imaging atherosclerosis markers

Mann-Whitney U test uncovered a correlation between LVDD and arterial atherosclerosis burden as reflected by

**Table 1. Continued**

| Continuous parameters (integer numbers) | LVDD present | LVDD absent |
|-----------------------------------------|--------------|-------------|
|                                         | Mean ± SD    | Median (q1-q3) | Mean ± SD | Median (q1-q3) |
| Aortic calcification total score        | 5.88 ± 5.72  | 4.5 (0.75-9)   | 2.16 ± 2.65  | 2 (0-3.5) |
| Number of carotid plaques               | 4.72 ± 4     | 4 (1.75-7.25)  | 3.58 ± 3.44  | 4 (0-5.5) |
| Number of femoral plaques               | 7.81 ± 4.21  | >10 (3->10)    | 5.11 ± 5.26  | 2 (0->10) |

| Categorical parameters                  | LVDD present | LVDD absent |
|-----------------------------------------|--------------|-------------|
|                                       | Yes (# patients) | No (# patients) | Yes (# patients) | No (# patients) |
| Male gender                            | 22           | 10          | 8             | 11           |
| Obesity                                | 8            | 24          | 5             | 14           |
| Overweight                             | 16           | 16          | 13            | 6            |
| Underweight                            | 1            | 31          | 1             | 18           |
| Carotid plaques                        | 27           | 5           | 15            | 4            |
| Femoral plaques                        | 31           | 1           | 14            | 5            |
| Aortic annulus calcifications          | 18           | 14          | 4             | 15           |
| Aortic valve calcifications            | 19           | 13          | 6             | 13           |
| Aortic valve/annulus calcifications    | 23           | 9           | 8             | 11           |
| Degenerative aortic stenosis           | 7            | 25          | 0             | 19           |
| Degenerative aortic regurgitation      | 6            | 26          | 2             | 17           |
| Mitral valve calcifications            | 19           | 13          | 5             | 14           |
| Mitral regurgitation                   | 13           | 19          | 6             | 13           |
| Pulmonary hypertension                 | 5            | 27          | 1             | 18           |

LVDD, left ventricular diastolic dysfunction; SD, standard deviation; q1/q3, first/third quartile; #patients, number of patients.

**Figure 1.** Associations between left ventricular diastolic dysfunction and inflammation, oxidative stress, number of femoral plaques, and the aortic calcification score. \(P\) values were calculated by means of Mann-Whitney U test.
Left ventricular dysfunction

the number of femoral plaques and the aortic calcification score (Table 3 and Figure 1).

Fisher’s exact test revealed associations between LVDD and most of the imaging atherosclerosis markers (but for aortic valve calcifications and carotid plaques) (Table 3). There was no association between LVDD and aortic or mitral valve regurgitation or pulmonary hypertension.

The most obvious putative confounder is degenerative aortic stenosis which by itself engenders LVDD (via the LVH it induces (21)) and is expected to be correlated with degenerative changes in other cardiac and arterial structures as CKD induces widespread valvular and arterial calcifications (22). All our patients with aortic valve stenosis also had LVDD. Therefore, the statistical computations needed to be repeated after eliminating this possible confounder, i.e. after eliminating the seven patients with aortic stenosis.

None of the associations between LVDD and IAMs (presence of femoral plaques, of aortic annulus calcifications, and of mitral valve calcifications) remained statistically significant after removing the seven patients with aortic stenosis.

Discussion

Although multiple mechanisms have been identified explaining myocardial hypertrophy and fibrosis underlying LVDD in hemodialysis patients (5), the biochemical and imaging associations relevant for clinical practice have been less explored. Our study, aimed at contributing to this under researched area, revealed some data concordant with what is already known, but also some differences.

The statistical analysis of our data indicated that in hemodialysis patients there is an association between LVDD and inflammation, as reflected by CRP, which is in agreement with the association between LVDD and high-sensitivity CRP (hs-CRP) in CKD patients demonstrated by other researchers (1), and is at least partially explained by the correlation between LVH and CRP in pre-dialysis patients (9) and in patients on hemodialysis (10) and with hs-CRP in hemodialysis patients (23), hs-CRP being an independent predictor for LVH in CKD (11).

However, we found no correlation between LVDD and other inflammatory markers, such as IL-6 and TNF-α (in agreement with previous studies on CKD patients.

Table 2. Associations between left ventricular diastolic dysfunction (categorical parameter) and inflammation and oxidative stress related parameters (numerical parameter) assessed by Mann-Whitney U test

| Numerical parameter        | LVDD Present median (q1-q3) | LVDD Absent median (q1-q3) | W statistic | P value |
|----------------------------|-----------------------------|-----------------------------|-------------|---------|
| CRP (mg/dL)                | 5.7 (0.875-14.7)            | 1.9 (0.1-4.7)               | 409.5       | 0.04    |
| Total antioxidant capacity (U/mL) | 26.2 (21.875-29.425)       | 22 (20-26.6)                | 410         | 0.04    |
| Cortisol (µg/dL)           | 13.4 (10.025-15.975)       | 15.1 (12.5-19.5)            | 201.5       | 0.05    |
| Number of femoral plaques | >10 (3->10)                | 2 (0->10)                   | 401         | 0.04    |
| Aortic calcification score | 4.5 (0.75-9)               | 2 (0-3.5)                   | 425         | 0.02    |

Table 3. Results of the Fisher’s exact test for the association between left ventricular diastolic dysfunction and imaging atherosclerosis markers

| IAM                        | DD+IAM+ | DD+IAM- | DD-IAM+ | DD-IAM- | P value | Odds ratio |
|----------------------------|---------|---------|---------|---------|---------|------------|
| Femoral plaques            | 31      | 1       | 14      | 5       | 0.022   | 10.54      |
| Aortic valve stenosis      | 7       | 25      | 0       | 19      | 0.037   | Infinite   |
| Aortic annulus calcifications | 18      | 14      | 4       | 15      | 0.02    | 4.67       |
| Aortic valve/annulus calcifications | 23      | 9       | 8       | 11      | 0.044   | 3.42       |
| Aortic valve calcifications | 19      | 13      | 6       | 13      | 0.083   | 3.09       |
| Mitral valve calcifications | 19      | 13      | 5       | 14      | 0.041   | 3.98       |

DD, diastolic dysfunction; IAM, imaging atherosclerosis marker. The columns 2-5 contain the number of patients in the four categories: diastolic dysfunction present with positive IAM (DD+IAM+), diastolic dysfunction present with negative IAM (DD+IAM-), diastolic dysfunction absent with positive IAM (DD-IAM+), diastolic dysfunction absent with negative IAM (DD-IAM-).
(1)), although other researchers demonstrated that LVH is associated with TNF-α in CKD patients (11) and in hemodialysis patients (23) and with IL-6 in CKD patients (1) and in hemodialysis patients (23).

The association of LVDD with oxidative stress demonstrated by our study is concordant with the findings of other researchers linking diastolic function to overproduction of ROS due to the involvement of oxidative stress in promoting cardiac remodeling (5) in CKD patients.

Our study failed to demonstrate a relation between LVDD and anemia, although there are studies suggesting that in CKD patients anemia is correlated with cardiac hypertrophy (24) and with left ventricular dilatation and heart failure (25).

We did not find an association between LVDD and disorders of bone and mineral metabolism, although other studies demonstrated that in hemodialysis patients LVDD is correlated with serum phosphorus level and calcium × phosphate product (13), while LVH is associated with serum PTH (13), phosphorus, and calcium level (13), and with vitamin D deficiency (16). Interestingly, in uremic rats cardiac fibrosis is associated with high serum parathormone level (15) and with hyperphosphatemia (14).

Conclusion
LVDD is positively correlated with inflammation and oxidative stress markers and with the severity of aortic calcification. The association of LVDD with valvular and peripheral arterial calcifications / atherosclerosis is largely mediated by its association with degenerative aortic stenosis. The purpose of designing therapeutic strategies is to prevent or slow the course of LVDD, thereby influencing the cardiovascular and general outcomes of these patients.

Limitations of the study
The most important limitations of this study are; 1. The relatively low number of enrolled patients. 2. The time interval the imaging investigation lagged behind the performance of laboratory tests; however, this delay was unavoidable given the ultrasound examination, as a human-dependent investigation, is inherently more labor- and time-intensive than laboratory tests, which are machine-dependent. 3. The putative confounders, among which degenerative aortic stenosis was probably the most important; the elimination of this confounding factor resulted in an even smaller sample of patients on which to base our conclusions. Studies on larger samples are necessary to identify the biochemical correlates/markers/determinants of LVDD in hemodialysis patients.

Authors’ contribution
Conceptualization: DD, DT, AEBS, MMM and DI. Methodology: DD, DT, MMM and DI. Validation: DD, DT, AEBS, MIG, MMM, IAV and DI. Formal analysis: DD, DT, AEBS, MMM and DI. Investigation: DD, DT, AEBS and MMM. Resources: DD, DT, AEBS and DI. Data curation: DD, DT and MMM. Writing—original draft preparation: DD, DT, AEBS, MIG, MMM and DI. Writing—review and editing: DD, DT, AEBS, MMM and DI. Visualization: DD and DT. Supervision: DD, DT and DI. Project administration: DD, DT and DI.

Conflicts of interest
The authors declare that they have no competing interests.

Ethical issues
The research followed the tenets of the Declaration of Helsinki. The Ethics Committee of University Emergency Hospital Bucharest approved this study. Accordingly, written informed consent was taken from all participants.

Funding/Support
None.

References
1. Gupta J, Dominic EA, Fink JC, Ojo AO, Barrows IR, Reilly MP, et al; CRIC Study Investigators. Association
between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One. 2015;10:e0124772. doi: 10.1371/journal.pone.0124772.
2. Escoli R, Carvalho MJ, Cabrita A, Rodrigues A. Diastolic Dysfunction, an Underestimated New Challenge in Dialysis. Ther Apher Dial. 2019;23:108-117. doi: 10.1111/1744-9987.12756.
3. Díez J, Laviades C. La cardiopatía hipertensiva en el paciente con enfermedad renal crónica [Hypertensive heart disease in the patient with chronic kidney disease]. Nefrologia. 2008;28:135-42. [Spanish].
4. Nardi E, Mulé G, Giammanco A, Mattina A, Geraci G, Nardi C, et al. Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison. Nutr Metab Cardiovasc Dis. 2021;31:137-144. doi: 10.1016/j.numecd.2020.08.028.
5. Kaelser N, Babler A, Floege J, Kramann R. Cardiac Remodeling in Chronic Kidney Disease. Toxins (Basel). 2020;12:161. doi: 10.3390/toxins12030161.
6. Peconi-Filho R, Bucharles S, Barberato SH. Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment. Semin Dial. 2012;25:35-41. doi: 10.1111/j.1525-139X.2011.01011.x.
7. Benz K, Hilgers KE, Daniel C, Amann K. Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. Int J Nephrol. 2018;2018:4310379. doi: 10.1155/2018/4310379.
8. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. Cardiorenal Med. 2015;5:254-66. doi: 10.1159/000435838.
9. Ortega O, Galtar P, Muñoz M, Rodríguez I, Carreño A, Ortiz M, et al. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract. 2004;97:c125-30. doi: 10.1159/000079170.
10. Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, et al. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189-95. doi: 10.1159/000085585.
11. Cottone S, Nardi E, Mulè G, Vadala A, Lorio MC, Riccobene R, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67:209-16. doi: 10.5414/cnp07209.
12. Hazin MAA. Anemia in chronic kidney disease. Rev Assoc Med Bras (1992). 2020;66:s55-s58. doi: 10.1590/1806-9282.66.S1.55.
13. Stróżecki P, Adamowicz A, Nartowicz E, Odrozaw-Sypniewska G, Włodarczyk Z, Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotenensive hemodialysis patients. Ren Fail. 2001;23:115-26. doi: 10.1081/jdi-100001291.
14. Amann K, Törnig J, Kugel B, Gross ML, Tyrlalla K, El-Shakmak A, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;63:1296-301. doi: 10.1046/j.1523-1755.2003.00864.x.
15. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994;4:1814-9. doi: 10.1681/ASN.V410181.
16. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Meister H, Mehl A, et al. Hypovitaminosis D is associated with systemic inflammation and concentric myocardial geometric pattern in hemodialysis patients with low iPTH levels. Nephron Clin Pract. 2011;118:c384-91. doi: 10.1159/000323664.
17. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314. doi: 10.1016/j.echo.2016.01.011.
18. Prasad SB, Holland DJ, Atherton JJ, Whalley G. New Diastology Guidelines: Evolution, Validation and Impact on Clinical Practice. Heart Lung Circ. 2019;28:1411-20. doi: 10.1016/j.hlc.2019.03.013.
19. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132:245-50. doi: 10.1016/s0021-9150(97)00106-8.
20. Yates D, Moore D, McCabe G. The Practice of Statistics. 1st ed. Freeman WH, editor. New York; 1999. p. 734.
21. Sobczak S, Sakowicz A, Pietrucha T, Lelonke M. Diagnostic utility of biomarkers of left ventricular stress in patients with aortic stenosis and preserved left ventricular ejection fraction. Kardiochir Torakochirurgia Pol. 2017;14(2):93-98. doi: 10.5114/ktp.2017.68737.
22. Ureña-Torres P, D’Marco L, Raggi P, García-Moll X, Brandenburg V, Mazzaferro S, et al. Valvular heart disease and calcification in CKD: more common than appreciated. Nephrol Dial Transplant. 2020;35:2046-2053. doi: 10.1093/ndt/gfaa133.
23. Shi L, Song J, Zhang X, Li Y, Li H. Correlation between the microinflammatory state and left ventricular structural and functional changes in maintenance haemodialysis patients. Exp Ther Med. 2013;6:532-536. doi: 10.3892/etm.2013.1131.
24. Silberberg JS, Rahal DP, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61. doi: 10.1016/s0272-6386(96)090130-4.

Copyright © 2022 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.